NCT06198907

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 69 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)

Conditions

• Non-Small-Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Golidocitinib	Daily dosing of golidocitinib
DRUG	Sintilimab	Sintilimab, 200mg, intravenous, every 3 weeks.
DRUG	platinum doublet chemotherapy	Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles

Timeline

• Start date: 2024-01-01
• Primary completion: 2026-12-01
• Completion: 2027-12-01
• First posted: 2024-01-10
• Last updated: 2024-01-10

Locations

1 site across 1 country: China